93
Participants
Start Date
October 31, 2013
Primary Completion Date
December 31, 2017
Study Completion Date
April 26, 2018
EC1456 and EC20
"EC1456 is small molecule drug conjugate of folic acid and tubulysin B hydrazide (TubBH) that specifically binds to the membrane-bound FR and gains entry into the cell via endocytosis.~EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc). When etarfolatide is labeled with 99mTc, the product (99mTc-etarfolatide) is able to quantify FR expressing tissues with SPECT imaging."
Weill Cornell Medical College, New York
Roswell Park Cancer Institute, Buffalo
University Hospitals Case Medical Center - Seidman Cancer Center, Cleveland
Indiana University Cancer Center, Indianapolis
IU Health Goshen Center for Cancer Care, Goshen
Horizon BioAdvance, Lafayette
Henry Ford Hospital - Josephine Ford Cancer Center, Detroit
Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago
Westchase Clinical Associates, Houston
University of Texas MD Anderson Cancer Center, Houston
Mayo Clinic, Phoenix
Honor Health, Scottsdale
University of Arizona Cancer Center, Tucson
City of Hope, Duarte
University of Maryland-Greenebaum Cancer Center, Baltimore
University of Vermont Cancer Center, Burlington
Lead Sponsor
Endocyte
INDUSTRY